Burrill & Company, which invests exclusively in the life sciences, manages funds totaling over $950 million. The San Francisco-based firm primarily invests in the United States and Europe. Managers at Burrill & Co. prefer early-stage opportunities, but invest across the industry, including in therapeutics, diagnostics, medical device companies, bioprocesses and biomaterials. The firm is currently investing its sixth fund, Burrill Life Sciences Capital Fund III, which closed in 2006 at $283 million.